Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (37)	6/5/2003 3:29:31 AM
From: Thomas	Read Replies (1) \| Respond to of 671

Thanks, SemiBull. That is intriguing news. Do any of those here who are "so wise in the ways of science" have a view on the basis for the claims in the press release-- specifically that their [proprietary?] ddRNAi approach is capable of permanent v. transient gene knockdown/silencing and that it does not provoke interferon response? Are these issues that Sirna needs work around? The Benitec folks imply that ddRNAi has more delivery options than siRNA-- can someone shed some light on that? Also, how does 1998 look to people as a priority date? Sounds pretty early from what I remember about the history of RNAi. Benitec has exclusively licensed ddRNAi IP to Promega (privately held biotech company in WI). Thanks in advance. Cheers, Thomas